ATTAIN-1: Orforglipron Phase 3 trial (NCT05869903)
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)
At a glance
- Phase
- Phase 3
- Status
- Active, not recruiting
- Enrolment
- 3,127
- actual
- Start
- 5 Jun 2023 (actual)
- Primary completion
- 25 Jul 2025 (actual)
- Sponsor
- Eli Lilly and Company
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Placebo | Placebo comparator | Drug: Placebo | Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron-matching placebo, administered orally once daily (QD), for a period of 72 weeks. |
| 6 mg Orforglipron | Experimental | Drug: Orforglipron | Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron, administered orally QD, starting at a dose of 1 milligrams (mg) and escalated every 4 weeks until reaching a dose of 6 mg at week 8, which was then maintained up to week 72. |
| 12 mg Orforglipron | Experimental | Drug: Orforglipron | Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks until reaching a dose of 12 mg at week 12, which was then maintained up to week 72. |
| 36 mg Orforglipron | Experimental | Drug: Orforglipron | Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks until reaching a dose of 36 mg at week 20, which was then maintained up to week 72. |
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent Change From Baseline in Body Weight (Primary Treatment Period) | Baseline, Week 72 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Change From Baseline in Waist Circumference (Primary Treatment Period) | Baseline, Week 72 |
| Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period | Baseline, Week 72 |
| Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period | Baseline, Week 72 |
| Percent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period | Baseline, Week 72 |
| Change From Baseline in HbA1c (Primary Treatment Period) | Baseline, Week 72 |
| Change From Baseline in Fasting Serum Glucose (FSG) (Primary Treatment Period) | Baseline, Week 72 |
| Percent Change From Baseline in Fasting Insulin (Primary Treatment Period) | Baseline, Week 72 |
| Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period | Baseline, Week 72 |
| Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical Component and Mental Component) Scores - (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period | Baseline, Week 72 |
| Percent Change From Baseline in Body Weight (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization) | Baseline, Week 176 |
| Time to Onset of Type 2 Diabetes (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization) | Baseline through Week 176, Baseline through Week 190 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT05869903.
ATTAIN-1 as published in the New England Journal of Medicine
ATTAIN-1 randomised participants 3:3:3:4 to orforglipron 6, 12 or 36 mg or placebo daily for 72 weeks, as an adjunct to diet and physical activity.[2]
Weight changed by -7.5%, -8.4% and -11.2% on 6, 12 and 36 mg against -2.1% on placebo.[2]
On 36 mg, 54.6% lost 10% or more, 36.0% lost 15% or more and 18.4% lost 20% or more, against 12.9%, 5.9% and 2.8% on placebo.[2]
Adverse events caused discontinuation in 5.3 to 10.3% of orforglipron patients and 2.7% of placebo patients.[2]
The subgroup aged 65 and over
The post hoc analysis covered 616 randomised participants aged 65 or older across the two phase 3 trials.[3]
In the ATTAIN-1 older subgroup, weight changed by -7.9%, -11.3% and -13.0% with the three orforglipron doses, against -1.6% with placebo.[3]
Sources
- 1A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
- 3Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.Obesity pillars · 2026PMID 42577069Accessed 2 Oct 2026
Found an error? Report a correction.